AntiThrombotic Therapy for Community-Acquired Pneumonia
This study is looking at whether a blood thinner called heparin (specifically low molecular weight heparin like enoxaparin, dalteparin, or tinzaparin) can help patients admitted to the hospital with community-acquired pneumonia (CAP). CAP is a lung infection that develops outside of a hospital setting. Researchers want to see if heparin, given at a therapeutic dose, can improve patient outcomes compared to the usual care for preventing blood clots. The study will enroll about 4000 adults, aged 18 and older, who have CAP confirmed by X-ray and symptoms like cough or fever. The main goal is to see how many people survive 30 days after starting treatment. The current recruitment status is unclear.
- Study design
- This is an international, open-label, randomized controlled trial comparing therapeutic-dose heparin to usual care in about 4000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' survival will be measured at 30 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
At a glance
Conditions
Where it's being run
64 sites across 23 statesStudy leadership
- Ryan Zarychanski, MD · PRINCIPAL_INVESTIGATOR · University of Manitoba
- Patrick Lawler, MD · PRINCIPAL_INVESTIGATOR · University Health Network and McGill University
- Sylvain Lother, MD · PRINCIPAL_INVESTIGATOR · University of Manitoba
- Alexis Turgeon, MD · PRINCIPAL_INVESTIGATOR · L'Universite Laval
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Ordinal endpoint reflecting survival30 days
Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications.